Faculty Opinions recommendation of Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer.

Randomized Study ◽

Metastatic Breast ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Double Blind ◽

Abstract CT212: A phase III randomized study of paclitaxel (T) and trastuzumab (H) versus T, H and lapatinib (L) in first line treatment of HER2+ metastatic breast cancer (MBC)

10.1158/1538-7445.am2020-ct212 ◽

2020 ◽

Author(s):

John Crown ◽

William Jacot ◽

Denis M. Collins ◽

Linda Coate ◽

Anna Saetersdal ◽

...

Keyword(s):

Breast Cancer ◽

Randomized Study ◽

Metastatic Breast ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Abstract OT1-1-06: A phase III randomized study of Paclitaxel and Trastuzumab versus Paclitaxel, Trastuzumab and Lapatinib in first line treatment of HER2 positive metastatic breast cancer.

10.1158/0008-5472.sabcs12-ot1-1-06 ◽

2012 ◽

Cited By ~ 1

Author(s):

JP Crown ◽

B Moulton ◽

N O'Donovan

Keyword(s):

Breast Cancer ◽

Randomized Study ◽

Metastatic Breast ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Her2 Positive ◽

Clinical Benefit Rate and Time to Response in RIBBON-1, a Randomized, Double-Blind, Phase III Trial of Chemotherapy with or without Bevacizumab (B) for the First-Line Treatment of HER2-Negative Locally Recurrent or Metastatic Breast Cancer (MBC).

10.1158/0008-5472.sabcs-09-6084 ◽

2009 ◽

Cited By ~ 4

Author(s):

N. Robert ◽

V. Dieras ◽

J. Glaspy ◽

A. Brufsky ◽

I. Bondarenko ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Double Blind ◽

Phase Iii Trial ◽

Locally Recurrent ◽

MARIANNE: A phase III, randomized study of trastuzumab-DM1 (T-DM1) with or without pertuzumab (P) compared with trastuzumab (H) plus taxane for first-line treatment of HER2-positive, progressive, or recurrent locally advanced or metastatic breast cancer (MBC).

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.tps102 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. TPS102-TPS102 ◽

Cited By ~ 15

Author(s):

P. A. Ellis ◽

C. H. Barrios ◽

Y. Im ◽

M. Patre ◽

F. Branle ◽

...

Keyword(s):

Breast Cancer ◽

Randomized Study ◽

Locally Advanced ◽

Metastatic Breast ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Her2 Positive ◽

A phase II randomized study comparing navelbine and capecitabine (Navcap) followed either by Navcap or by weekly docetaxel in the first-line treatment of HER-2/neu negative metastatic breast cancer

Medical Oncology ◽

10.1007/s12032-010-9754-2 ◽

2010 ◽

Vol 28 (S1) ◽

pp. 142-151 ◽

Cited By ~ 3

Author(s):

M. Ghosn ◽

P. Aftimos ◽

F. S. Farhat ◽

J. G. Kattan ◽

C. Hanna ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Randomized Study ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Weekly Docetaxel ◽

Her 2 ◽

5016 Efficacy in patient subgroups in RIBBON-1, a randomized, double-blind, Phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC)

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(09)70908-5 ◽

2009 ◽

Vol 7 (2) ◽

pp. 265 ◽

Cited By ~ 15

Author(s):

V. Dieras ◽

J. Glaspy ◽

A. Brufsky ◽

I. Bondarenko ◽

O. Lipatov ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Double Blind ◽

Phase Iii Trial ◽

Locally Recurrent ◽

Patient Subgroups ◽

Phase III study of liposome-encapsulated doxorubicin (TLC D-99) and cyclophosphamide (CPA) vs. epirubicin (EPI) and CPA in first-line treatment of metastatic breast cancer (MBC)

European Journal of Cancer ◽

10.1016/s0959-8049(99)81679-7 ◽

1999 ◽

Vol 35 ◽

pp. S315 ◽

Cited By ~ 2

Author(s):

S. Chan ◽

N. Davidson ◽

E. Juozaityte ◽

F. Erdkamp ◽

L. Hooftman ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Phase Iii Study ◽

Prospective Multicenter Randomized Phase III Study of Weekly versus Standard Docetaxel (D2) for First-Line Treatment of Metastatic Breast Cancer

Oncology ◽

10.1159/000320640 ◽

2010 ◽

Vol 79 (3-4) ◽

pp. 197-203 ◽

Cited By ~ 11

Author(s):

Hans-Joachim Stemmler ◽

Nadia Harbeck ◽

Isolde Gröll de Rivera ◽

Ursula Vehling Kaiser ◽

Gerhard Rauthe ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Phase Iii Study ◽

Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment of MBC

Anti-Cancer Drugs ◽

10.1097/01.cad.0000175587.31940.19 ◽

2005 ◽

Vol 16 (8) ◽

pp. 871-877 ◽

Cited By ~ 44

Author(s):

G. von Minckwitz ◽

I. Chernozemsky ◽

L. Sirakova ◽

P. Chilingirov ◽

R. Souchon ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Progression Free Survival ◽

Multicenter Trial ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Free Survival ◽

Randomized phase III study of trastuzumab monotherapy followed by docetaxel and trastuzumab versus the combination of trastuzumab and docetaxel as first-line treatment in patients with HER2 positive metastatic breast cancer.

10.1158/0008-5472.sabcs-3132 ◽

2009 ◽

Cited By ~ 3

Author(s):

K Najagami ◽

K Inoue ◽

M Mizutani ◽

Y Hozumi ◽

Y Fujiwara ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Her2 Positive ◽

Phase Iii Study ◽

Trastuzumab Monotherapy ◽